Biopreparedness Act of 2005
This article was originally published in The Gray Sheet
Executive Summary
Product liability provisions in S 3 address perceived shortcomings of Bioshield Act of 2004. The new language, including a noneconomic damages cap of $250,000 - awardable only for physical harm - would benefit manufacturers, distributors and providers of any "equipment, service (including support services), device, or technology (including information technology) designed...for the specific purpose of preventing, detecting, identifying, or preventing a pandemic or epidemic." Introduced Jan. 24 by Sen. Judd Gregg (R-N.H.), the bill was referred to the Finance Committee...
You may also be interested in...
BioShield Law Deflects Devices With Commercial Opportunity – Aethlon CEO
BioShield requirements related to stockpile purchases of medical countermeasures should be made less restrictive, according to Aethlon Medical CEO James Joyce
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.